Novokinin (RPLKPW), LPYPR, and rubiscolin (YPLDLF) are bioactive peptides with respective hypotensive, hypocholesterolemic, and memory-enhancing activities. We generated transgenic soybean lines that expressed modified forms of the 0 subunit of seed storage protein -conglycinin containing tandem repeats of these bioactive peptides. The modified 0 subunits constituted up to 0.2% of extracted proteins from the transgenic seeds.
Many food proteins contain diverse bioactive peptides within their primary structures. However, in general, the activities of these peptides are too low for their benefits to be experienced during normal food intake. The incorporation of multiple copies of such bioactive peptides into food proteins by genetic engineering is a potential solution to this problem and would facilitate dietetic therapy.
We have previously identified several bioactive peptides that were effective after an oral administration. Novokinin (RPLKPW) is a potent hypotensive peptide that was rationally designed on the basis of amino acids 2 to 7 of ovokinin (RADHPF), which is itself derived from ovalbumin. 1, 2) Novokinin reduced the blood pressure of spontaneously hypertensive rats after its oral administration at a dose of 0.1 mg per kilogram of body mass. LPYPR is a peptide with hypocholesterolemic activity whose sequence is present within that of the A 5 A 4 B 3 subunit of glycinin, a major soybean protein. 3, 4) LPYPR exhibited hypocholesterolemic activity at a dose of 50 mg/kg in mice. It also appeared to possess memory-enhancing activity after either a central or oral administration. 5) Rubiscolin (YPLDLF) is a -opioid peptide present within spinach D-ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco). 6) In a step through-type passive avoidance test in mice, rubiscolin enhanced memory consolidation at an oral dose of 100 mg/kg. 7) Rubiscolin also exerted an anxiolytic-like effect in the elevated plus-maze test after its oral administration to mice at a dose of 100 mg/kg. 8) Soybean [Glycine max (L.) Merr.] is an attractive option for the production and storage of foreign proteins by plant molecular farming, given that soybean seeds contain a large amount of total protein (%40% of the seed dry weight). We have previously used the 0 subunit of -conglycinin (CG 0 ), one of the major storage proteins of soybean seeds, as a carrier protein for novokinin, with the peptide being incorporated into CG 0 at four sites by minimum replacement of the amino acids constituting analogous sequences. 9) An oral administration of transgenic soybean seeds that accumulated the modified protein, designated 4novokinin-0 , resulted in a reduction in the systemic blood pressure of spontaneously hypertensive rats. 10) This strategy is laborious, however, and it is therefore important to identify the substitution sites of carrier proteins suitable for the incorporation of different bioactive peptides. CG 0 is synthesized as a preproprotein and subsequently processed into the mature form. The mature form of CG 0 possesses a core region, and also an extension region (residues 63 to 203) that is not essential for protein folding (Fig. 1A) . 11) We have now designed modified forms of CG 0 in which a portion of the extension region is replaced by tandem repeats of three different bioactive peptides. We were able to generate transgenic soybean lines that accumulated these various modified forms of CG 0 . We replaced residues 77 to 195 (site A) of CG 0 ( Fig. 1B) (Fig. 1C) . To facilitate the release of novokinin from the carrier protein by digestive enzymes in the intestines, we inserted arginine and glutamine residues at the ends of each tandem repeat. 1, 9) Trypsin predominantly cleaves proteins at the carboxyl side of lysine and arginine, except when either is followed by proline. In addition, chymotrypsin cleaves peptides at the carboxyl side of tyrosine, tryptophan, and phenylalanine. Furthermore, we have previously elucidated that the addition of glutamine at the carboxyl side of tryptophan enhanced the release of a novokinin peptide. 9) Therefore, trypsin and chymotrypsin would be able to cleave RjRPLKPWjQ (j indicates the cleavage site) to release the novokinin. We also replaced site A of CG 0 with seven tandem repeats of LPYPR to generate Tr7LPYPR-0 (Fig. 1C) . To facilitate the release of LPYPR by trypsin, we inserted an arginine residue before the first tandem repeat sequence. We also designed Tr7L7Y-0 , in which seven copies of the rubiscolin peptide in addition to seven LPYPR repeats were substituted for site A of CG 0 (Fig. 1C ). Rubiscolin contains a sequence that mediates its release by pepsin, 6) and we inserted an arginine residue before the first rubiscolin repeat.
The genes encoding the modified CG 0 proteins were individually inserted into a transformation vector. The expression plasmid, pEC 0 , 11) which was derived from pET21d(þ) (Novagen) and harbors the cDNA encoding CG 0 between the NcoI and BamHI sites, was modified to simplify the insertion of the transgenes. AatII and AflII restriction sites were thus respectively generated by site-directed mutagenesis of nucleotides 231 and 581, relative to the initiation codon, thereby yielding pEC 0 AA. Artificial genes flanked by the AatII and AflII sites and encoding either four novokinin repeats, seven LPYPR repeats, or seven LPYPR and seven rubiscolin repeats ( Fig. 2A) were synthesized (Hokkaido System Science, Hokkaido, Japan) and subcloned into the AatII and AflII sites of pEC 0 AA. The AflII site was then replaced with a sequence encoding arginine or glutamic acid by site-directed mutagenesis to yield pET: Tr4novokinin-0 , pET:Tr7LPYPR-0 , or pET:Tr7L7Y-0 ( Fig. 2A) . A DNA fragment between BsmI (208 bp downstream of the initiation codon) and SacI (1402 bp downstream of the initiation codon) sites of pUHG: 4novokinin-0 , 10) which encodes portions of the extension and core regions, was replaced by the corresponding sequences of pET:Tr4novokinin-0 , pET:Tr7LPYPR-0 , or pET:Tr7L7Y-0 to generate the plant transformation vectors pUHG:Tr4novokinin-0 , pUHG:Tr7LPYPR-0 , and pUHG:Tr7L7Y-0 , respectively (Fig. 2B) . The identity of the vector inserts was confirmed by DNA sequencing.
The transformation vectors were introduced into soybean (cv. Jack) somatic embryos by particle bombardment, and transgenic plants were then regenerated as previously described. 12) Proteins were extracted from T 1 seeds with a 1Â SDS sample buffer [50 mM TrisHCl (pH 8.0), 0.2% SDS, 5 M urea, and 2% -mercaptoethanol] and were subjected to an immunoblot analysis with antisera prepared by injecting rabbits with the synthetic peptide, RPLKPWC (for novokinin) 10) or CLPYPRLPYPR (for LPYPR). The Tr4novokinin-0 (predicted molecular mass of 55 kDa), Tr7LPYPR-0 (predicted molecular mass of 55 kDa), and Tr7L7Y-0 (predicted molecular mass of 64 kDa) proteins were each detected in at least two independent transgenic lines ( Fig. 3) , although not all the seeds accumulated the modified CG 0 subunits because we examined T 1 seeds segregating the transgenes. Whereas both Tr7LPYPR-0 and Tr7L7Y-0 were detected at the expected molecular sizes, the apparent size of Tr4novokinin-0 (about 50 kDa) was smaller than expected. This discrepancy might be attributable to digesting the full-length protein at its COOH-terminus, given that the antibodies recognized the novokinin sequence in the NH 2 -terminal region.
Densitometry of the immunoreactive bands corresponding to the modified CG 0 proteins in soybean seeds, in comparison with those corresponding to recombinant 4novokinin-09) or Tr7LPYPR-0 produced in Escherichia coli, suggested that the abundance of the modified CG 0 subunits was about 0.1-0.2% of the extracted protein (roughly estimated, this amount corresponds to about 1-2 mg of novokinin peptide per 100 mg of seed) for Tr4novokinin-0 , about 0.05% (similarly, about 1 mg of LPYPR peptide per 100 mg of seed) for Tr7LPYPR-0 , and <0:05% (similarly, <1 mg of each peptide per 100 mg of seed) for Tr7L7Y-0 . We have previously reported that 4novokinin-0 , in which novokinin peptides were inserted by minimum replacement of amino acids in the extension region of CG 0 , accumulated 0.5% of the extracted protein (this value corresponds to 5 mg of novokinin peptide per 100 mg of seed).
9) The accumulation level of Tr4novokinin-0 was slightly lower than that of 4novokinin-0 . Even though there is a possibility that the difference in transformation methods (particle bombardment in this study and the whisker method in the previous study) affected the accumulation level, large-scale insertion of repetitive peptides might slightly depress the efficiency of protein synthesis. Nevertheless, the insertion of repetitive peptides into carrier proteins would be applicable for various peptides, since it is a sequence-independent insertion method, unlike insertion by the modification of analogous sequences. We did not determine whether the bioactive peptides exhibited their characteristic effects after an oral administration of the transgenic soybean seeds. In our previous study, defatted seed flour of transgenic soybean, in which 4novokinin-0 produced by site-directed mutagenesis constituted 0.5% of the extracted protein, reduced the systemic blood pressure of spontaneously hypertensive rats after an oral admin- istration at a dose of 0.25 g/kg. 10) On the basis of this result, defatted flour of transgenic soybean seeds accumulating Tr4novokinin-0 could be expected to exhibit the same effect at a dose of 0.63-1.25 g/kg. The expression levels of Tr7LPYPR-0 and Tr7L7Y-0 in the transgenic soybean seeds were too low to examine their effects in animals, given that the LPYPR and rubiscolin peptides were less potent than novokinin.
4,7)
The utilization of transgenic soybean lines producing these bioactive peptides as beneficial foods will thus require improving the effectiveness of the peptides by amino acid replacement, an increase in the number of peptide repeats inserted into the carrier protein, or an increase in the expression level of the modified proteins.
In addition to the accumulation in soybean seeds of fusion proteins containing bioactive peptides described in the present study, a hybrid peptide (7Crp) comprising seven T cell epitopes of Japanese cedar pollen allergens Cryj1 and Cryj2 has been shown to accumulate in rice endosperm without the use of a carrier protein. 13, 14) However, 7Crp did not accumulate in other tissues including the embryo, even though the promoter used to drive its expression was functional in these tissues as well as in endosperm.
14) Quality control of protein biogenesis might thus be less stringent in the endosperm than in the other tissues examined. Given that soybean stores proteins in the embryo, this strategy might not be applicable to soybean. Carrier proteins may thus be necessary for accumulating exogenous peptides in soybean, and our present results suggest that the extension region of CG 0 would be an appropriate insertion site for various bioactive peptides. 
